FWP
MREO

Forefront Wealth Partners’s Mereo BioPharma MREO Stock Holding History

Forefront Wealth Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,180
Closed -$68.4K – 176
2025
Q3 		$68.4K Buy
+33,180
New +$61.2K 0.02% 190

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Forefront Wealth Partners's MREO Position: Q4 2025 in Review

Forefront Wealth Partners sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 33,180 shares — an estimated $68.4K sold.

Forefront Wealth Partners first reported a position in MREO in Q3 2025 and held it in 1 quarter. The position peaked at $68.4K in Q3 2025. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Forefront Wealth Partners reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Forefront Wealth Partners sold 33,180 Mereo BioPharma shares in Q4 2025, an estimated $68.4K.
  • Forefront Wealth Partners first reported a position in Mereo BioPharma in Q3 2025 and held it in 1 quarter.
  • Forefront Wealth Partners's Mereo BioPharma position peaked at $68.4K in Q3 2025.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Forefront Wealth Partners's 13F filing for Q4 2025, filed 6 Feb 2026.